$11.26+0.26 (+2.36%)
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Telix Pharmaceuticals Limited in the Healthcare sector is trading at $11.26. The stock is currently 40% below its 52-week high of $18.87, remaining 17.5% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why TLX maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therape...
Those following along with Telix Pharmaceuticals Limited ( ASX:TLX ) will no doubt be intrigued by the recent purchase...
Earlier this week, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA trial dosimetry results for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in key non-target organs and supporting further evaluation in earlier-stage disease. The data suggest TLX597-Tx may allow higher treatment doses while limiting toxicity, potentially expanding access to lutetium-based therapy across more prostate cancer patients and geographies. We’ll now explore how these...
Telix Pharmaceuticals (NASDAQ:TLX) hosted an educational webinar outlining its next-generation prostate-specific membrane antigen (PSMA) radiopharmaceutical strategy, with management and a clinical investigator emphasizing the need for more patient-centric dosing and improved tolerability as PSMA-ta
Regeneron will face competition from new market entrants later this year, but upbeat data could change everything.
Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best Australian stocks to buy in 2026. Telix Pharmaceuticals Limited (NASDAQ:TLX) is using a combination of internal programs and partnership arrangements to expand its product portfolio. On April 21, the company announced that it plans to present clinical trial data for its prostate cancer drug candidate at the […]